Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful hiv-associated polyneuropathies

Pain Medicine (United States)

Volumn 14, Issue 7, 2013, Pages 1039-1047

  Harrison, Taylor ^a   Miyahara, Sachiko ^b   Lee, Anthony ^b   Evans, Scott ^b   Bastow, Barbara ^c   Simpson, David ^d   Gilron, Ian ⁱ   Dworkin, Robert ^e   Daar, Eric S ^f   Wieclaw, Linda ^g   Clifford, David B ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ QUEEN S UNIVERSITY   (Canada)

Author keywords

Antidepressants; HIV; Neuropathic Pain; Opioids

Indexed keywords

DULOXETINE; MALLINCKRODT; METHADONE; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; BURN; COMORBIDITY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; HIV ASSOCIATED POLYNEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY DYSFUNCTION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; VOMITING;

EID: 84880580745     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12084     Document Type: Article

References (41)

1. Schifitto G, McDermott MP, McArthur JC, etal. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58(12):1764-1768.
2. Morgello S, Estanislao L, Simpson D, etal. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. Arch Neurol 2004;61(4):546-551.
3. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001;81(11):1537-1544.
4. Blum AS, Dal Pan GJ, Feinberg J, etal. Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors. Neurology 1996;46(4):999-1003.
5. Abrams DI, Goldman AI, Launer C, etal. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1994;330(10):657-662.
6. Berger AR, Arezzo JC, Schaumburg HH, etal. 2′, 3′-dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients. Neurology 1993;43(2):358-362.
7. Evans SR, Ellis RJ, Chen H, etal. Peripheral neuropathy in HIV: Prevalence and risk factors. AIDS 2011;25(7):919-928.
8. Ellis RJ, Rosario D, Clifford DB, etal. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER Study. Arch Neurol 2010;67(5):552-558.
9. Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 2005;32(2):201-204.
10. Pettersen JA, Jones G, Worthington C, etal. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59(5):816-824.
11. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150(3):573-581.
12. Kieburtz K, Simpson D, Yiannoutsos C, etal. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998;51(6):1682-1688.
13. Shlay JC, Chaloner K, Max MB, etal. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998;280(18):1590-1595.
14. Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: A double-blind, placebo-controlled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(4):367-372.
15. Estanislao L, Carter K, McArthur J, Olney R, Simpson D. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004;37(5):1584-1586.
16. Hahn K, Arendt G, Braun JS, etal. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004;251(10):1260-1266.
17. Simpson DM, Schifitto G, Clifford DB, etal. Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology 2010;74(5):413-420.
18. Simpson DM, McArthur JC, Olney R, etal. Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial. Neurology 2003;60(9):1508-1514.
19. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-2313.
20. Ellis RJ, Toperoff W, Vaida F, etal. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-680.
21. Abrams DI, Jay CA, Shade SB, etal. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007;68(7):515-521.
22. Gilron I, Bailey JM, Tu D. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-1334.
23. Gilron I, Bailey JM, Tu D. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet 2009;374(9697):1252-1261.
24. Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: Results of a multicenter Italian study. Eur Neurol 2009;61(3):129-137.
25. Raskin J, Pritchett YL, Wang F, etal. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6(5):346-356.
26. Wernicke JF, Pritchett YL, D'Souza DN, etal. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411-1420.
27. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116(1-2):109-118.
28. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-3052.
29. Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8(3):149-154.
30. Morley JS, Bridson J, Nash TP. Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med 2003;17(7):576-587.
31. Enggaard TP, Poulsen L, Arendt-Nielsen L, etal. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain 2001;92(1-2):277-282.
32. Luccarini P, Perrier L, Degoulange C, Gaydier AM, Dallel R. Synergistic antinociceptive effect of amitriptyline and morphine in the rat orofacial formalin test. Anesthesiology 2004;100(3):690-696.
33. Taiwo YO, Fabian A, Pazoles CJ, Fields HL. Potentiation of morphine antinociception by monoamine reuptake inhibitors in the rat spinal cord. Pain 1985;21(4):329-337.
34. Ellis RJ, Evans SR, Clifford DB, etal. Clinical validation of the NeuroScreen. J Neurovirol 2005;11(6):503-511.
35. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2010;5(12):e14433.
36. Robinson-Papp J, Morgello S, Vaida F, etal. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain 2010;151(3):732-736.
37. Katz MH, Douglas JM, Jr., Bolan GA, etal. Depression and use of mental health services among HIV-infected men. AIDS Care 1996;8(4):433-442.
38. Burnam MA, Bing EG, Morton SC, etal. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry 2001;58(8):729-736.
39. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001;158(5):725-730.
40. Kuehn BM. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 2007;297(3):249-251.
41. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363(21):1981-1985.